L. Reznickova

Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with superior prognosis

E. Mejstrikova, O. Hrusak, E. Froňková, 2011, Haematologica.

Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing?

E. Mejstrikova, O. Hrusak, E. Froňková, 2008, Leukemia.

CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage

T. Kalina, E. Mejstrikova, L. Slámová, 2014, Leukemia.

Detectable Minimal Residual Disease before Haematopoietic Stem Cell Transplantation Predicts Extremely Poor Prognosis in Children with Acute Lymphoblastic Leukaemia.

E. Froňková, J. Starý, J. Trka, 2005 .

TEL/AML1 real-time quantitative reverse transcriptase PCR can complement minimal residual disease assessment in childhood ALL

O. Hrusak, E. Froňková, J. Zuna, 2005, Leukemia.